Dan Maria E, Schiffer Charles A
Department of Pathology, Harper University Hospital, 3990 John R, Detroit, MI 48201, USA.
Curr Hematol Rep. 2003 Mar;2(2):158-64.
The availability of platelet transfusions made possible intensive, myelosuppressive therapy. Chronic transfusion support is often complicated by refractoriness to platelet transfusions characterized by inadequate post-transfusion platelet count increments. Refractoriness is most commonly associated with a variety of clinical factors. Aggressive treatment of these clinical conditions often corrects the response to platelet transfusions. Fewer patients develop immune-mediated platelet destruction associated with alloantibodies to class I human leukocyte antigens (HLAs) and occasionally to platelet-specific antigens. The majority of these patients are successfully supported with HLA-matched or cross-match compatible single-donor platelet concentrates.
血小板输注的可用性使强化骨髓抑制疗法成为可能。长期输血支持常常因对血小板输注产生不应性而变得复杂，其特征为输血后血小板计数增加不足。不应性最常与多种临床因素相关。积极治疗这些临床病症通常可纠正对血小板输注的反应。较少患者会出现与针对I类人类白细胞抗原（HLA）的同种抗体以及偶尔针对血小板特异性抗原的免疫介导的血小板破坏。这些患者中的大多数通过HLA匹配或交叉配型相容的单供体血小板浓缩物得到成功支持。
